Furthermore, in humans and mice, the CKD-driven increase in osteocyte secretion of Wnt/β-catenin‐signaling inhibitors such as FGF23, dickkopf 1, and sclerostin may negatively affect osteoblast function and contribute to the mineralization defect in ROD (Evenepoel et al. 2015, Murali et al. 2016a). Here, FGF23 is linked to chronic kidney disease.